AMD Fails to Impress Wall Street, But Cowen Sees AI Breakthroughs
In a Monday note, analyst Joshua Buchalter maintained a Buy rating, pointing to AMD's growing traction in the AI space. The event showcased its MI350 GPU lineup, enhancements to its ROCm 7 software, and teased the MI400 Helios rack-scale system slated for 2026.
Warning! GuruFocus has detected 3 Warning Signs with AMD.
While the absence of financial updates kept investors on the sidelines, Buchalter said AMD's roadmap shows promise. He likened the MI350 and MI400 to AMD's earlier CPU efforts that ultimately helped it close the gap with rivals.
A surprise appearance by OpenAI CEO Sam Altman offered a nod of validation, with praise for the forthcoming MI450X, which AMD aims to release in late 2026.
Seven of the ten largest AI firms are already using AMD chips, including early adopter Oracle (NYSE:ORCL), Meta (NASDAQ:META), and xAI. But Cowen says execution in 2H25 remains key to convincing investors AMD can scale and compete.
Based on the one year price targets offered by 41 analysts, the average target price for Advanced Micro Devices Inc is $130.84 with a high estimate of $200.00 and a low estimate of $95.00. The average target implies a upside of +12.64% from the current price of $116.16.
Based on GuruFocus estimates, the estimated GF Value for Advanced Micro Devices Inc in one year is $165.21, suggesting a upside of +42.23% from the current price of $116.16.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Xcel Energy Second Quarter 2025 Earnings Conference Call
MINNEAPOLIS, July 01, 2025--(BUSINESS WIRE)--On Thursday, July 31, 2025, Xcel Energy (NASDAQ: XEL) will host a conference call to review second quarter 2025 financial results. The earnings report will be released prior to the market open on the same date. The call will begin at 9:00 a.m. Central Time. To participate in the conference call, please dial in at least 10 minutes prior to the scheduled start and follow the operator's instructions. You will be asked for the conference password. US Dial-In: 1-866-580-3963International Dial-In: 400-120-0558Conference Password: 5768023 The conference call will be simultaneously webcast and archived on our website at the following location: Under Company, select: Investors If you are unable to participate in the live event, the call will be available for replay through August 5. Replay InformationUS Dial-In: 1-866-583-1035Replay Password: 5768023# About Xcel EnergyXcel Energy (NASDAQ: XEL) provides the energy that powers millions of homes and businesses across eight Western and Midwestern states. Headquartered in Minneapolis, the company is an industry leader in responsibly reducing carbon emissions and producing and delivering clean energy solutions from a variety of renewable sources at competitive prices. For more information, visit or follow us on X and Facebook. View source version on Contacts Financial analysts may call:Roopesh Aggarwal, Vice President - Investor Relations303-571-2855 News media inquiries please call:Xcel Energy Media Relations612-215-5300Internet: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Citi sees upside for Trade Desk into Q2 results, adds on a catalyst watch
-- Citi placed Trade Desk (NASDAQ:TTD) on a 90-day positive catalyst watch, citing signs of stronger ad spending and robust connected TV (CTV) trends ahead of the company's second-quarter earnings report. The brokerage said it came away 'incrementally more positive' on the outlook after meetings at the Cannes Lions advertising conference, suggesting that macro conditions have stabilized since Trade Desk issued Q2 guidance in early May. That improved backdrop, coupled with healthy CTV activity, may lead to results ahead of expectations, Citi said. The firm maintained a Buy rating and a $90 price target on the stock, noting Trade Desk's positioning as a leading independent demand-side platform. While it acknowledged investor concerns over competition from Amazon's DSP, Citi said Trade Desk remains differentiated and the broader programmatic ad market is large enough to support multiple players. Shares trade at roughly 26 times estimated 2026 EBITDA, according to Citi. A beat in Q2 could drive a re-rating back above 30 times, it said. Citi values the stock based on a blend of discounted cash flow, EV/revenue and EV/EBITDA multiples, noting the company's strong topline growth, consistent take rates, and margin profile amid a secular shift of ad dollars from linear TV to CTV. Related articles Citi sees upside for Trade Desk into Q2 results, adds on a catalyst watch Design platform Figma files for U.S. IPO CD&R joins race for BP's $8 billion Castrol unit, Sky News reports Sign in to access your portfolio
Business Wire
44 minutes ago
- Business Wire
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the 'Company' or 'Revelation'), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse stock split will be effective as of the morning of July 7, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol 'REVB.' The CUSIP number for the common stock following the reverse stock split will be 76135L705. The reverse stock split is intended to increase the market price per share of the Company's common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market. Proportionate adjustments will be made to the conversion and exercise prices of the company's warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the Company's equity incentive plans. Separately, the Company also announced that it's ongoing PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete enrollment this month and topline data expected shortly after. For more information on Revelation, please visit Information for Stockholders Upon the effectiveness of the reverse stock split, each sixteen shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's relative interest in the Company's equity, except to the extent that the reverse stock split would have resulted in a stockholder owning a fractional share. Holders of common stock otherwise entitled to a fractional share as a result of the Reverse Stock Split because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will be rounded down to the nearest whole share. The reverse stock split will not change the par value of the common stock or modify the rights or preferences of the common stock. The Company's transfer agent, Continental Stock Transfer & Trust Co., will maintain the book-entry records for the Company's common stock. Registered stockholders holding pre-split shares of the Company's common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker's particular processes, and will not be required to take any action in connect with the reverse stock split. Continental Stock Transfer & Trust Co. can be reached at (212) 509-4000 or (800)-509-5586. About Revelation Biosciences, Inc. Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease. For more information on Revelation, please visit Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
